G protein-coupled receptors: a gateway to targeting oncogenic EVs?

Dysregulated intercellular communication is a key feature driving cancer progression. Recently, extracellular vesicles (EVs) have added a new channel to this dense communication network. Despite solid evidence that EVs are central mediators of dysregulated signaling in onco-pathological settings, this has yet to be translated into clinically actionable strategies.

Constitutive activity of an atypical chemokine receptor revealed by inverse agonistic nanobodies.

Chemokine stimulation of atypical chemokine receptor 3 (ACKR3) does not activate G proteins but recruits arrestins. It is a chemokine scavenger that indirectly influences responses by restricting the availability of CXCL12, an agonist shared with the canonical receptor CXCR4. ACKR3 is upregulated in numerous disorders.

Techniques for modeling ocean soundscapes: Detailed description for wind contributionsa).

Wind over the ocean creates breaking waves that generate air-filled bubbles, which radiate underwater sound. This wind-generated sound is a significant component of the ocean soundscape, and models are essential for understanding and predicting its impact. Models for predicting sound pressure level (SPL) from wind have been studied for many years.

Verifying models of the underwater soundscape from wind and ships with benchmark scenariosa).

Models of the underwater acoustic soundscape are important for evaluating the effects of human generated sounds on marine life. The performance of models can be validated against measurements or verified against each other for consistency. A verification workshop was held to compare models that predict the soundscape from wind and vessels and estimate detection ranges for a submerged target.

Multivalent CXCR4-targeting nanobody formats differently affect affinity, receptor clustering, and antagonism.

The chemokine receptor CXCR4 is involved in the development and migration of stem and immune cells but is also implicated in tumor progression and metastasis for a variety of cancers. Antagonizing ligand (CXCL12)-induced CXCR4 signaling is, therefore, of therapeutic interest. Currently, there are two small-molecule CXCR4 antagonists on the market for the mobilization of hematopoietic stem cells.